Cargando…

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

Spartalizumab is a humanized IgG4/κ mAb directed against human programmed cell death‐1 (PD‐1). In this phase I study, we investigated safety, pharmacokinetics, preliminary antitumor activity, and toxicity of spartalizumab in patients with advanced malignancies. Patients (n = 18) with a range of tumo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Hironobu, Doi, Toshihiko, Toyoda, Masanori, Imamura, Yoshinori, Kiyota, Naomi, Mitsuma, Ayako, Shimokata, Tomoya, Naito, Yoichi, Matsubara, Nobuaki, Tajima, Takeshi, Tokushige, Kota, Ishihara, Kae, Cameron, Scott, Ando, Yuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893979/ https://www.ncbi.nlm.nih.gov/pubmed/33031626 http://dx.doi.org/10.1111/cas.14678

Ejemplares similares

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
por: Schöffski, Patrick, et al.
Publicado: (2022)

Antiprogramed cell death‐1 therapy with microspheres for metastatic liver tumors
por: Kamimura, Hiroteru, et al.
Publicado: (2019)

The epistemic culture in an online citizen science project: Programs, antiprograms and epistemic subjects
por: Kasperowski, Dick, et al.
Publicado: (2018)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
por: Sai, Satoshi, et al.
Publicado: (2021)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
por: Jo, Hitomi, et al.
Publicado: (2023)

Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR)
por: Dos Santos, Mélanie, et al.
Publicado: (2022)

Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors
por: Bauer, Todd M, et al.
Publicado: (2023)

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
por: Nishimura, Meiko, et al.
Publicado: (2016)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

Enhanced Inhibitory Effect of DC-CIK Cells on Lung Adenocarcinoma via Anti-Tim-3 Antibody and Antiprogrammed Cell Death-1 Antibody and Possible Mechanism
por: Zhou, Liang, et al.
Publicado: (2022)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
por: Funakoshi, Yohei, et al.
Publicado: (2016)

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
por: Chan, Stephen L., et al.
Publicado: (2022)

Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

ABC Transporter Pdr10 Regulates the Membrane Microenvironment of Pdr12 in Saccharomyces cerevisiae
por: Rockwell, Nathan C., et al.
Publicado: (2009)

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
por: Piha-Paul, Sarina A, et al.
Publicado: (2021)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Etoposide in a 14‐Day Infusion for Non‐small‐cell Lung Cancer
por: Ando, Yuichi, et al.
Publicado: (1996)

Therapeutic Drug Monitoring in 21‐Day Oral Etoposide Treatment for Lung Cancer
por: Ando, Yuichi, et al.
Publicado: (1996)

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019)

Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
por: Tawbi, Hussein A, et al.
Publicado: (2022)

Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study
por: Naderi-Azad, Sheida, et al.
Publicado: (2020)

Plasma Membrane Translocation of Fluorescent-labeled Phosphatidylethanolamine Is Controlled by Transcription Regulators, PDR1 and PDR3
por: Kean, Leslie S., et al.
Publicado: (1997)

Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study
por: Takenaka, Kei, et al.
Publicado: (2015)

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
por: Uemura, Hiroji, et al.
Publicado: (2017)

Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2019)

Pharmacokinetic Study of Carboplatin Given on a 5‐Day Intravenous Schedule
por: Ando, Yuichi, et al.
Publicado: (1997)

Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review
por: Maeda, Osamu, et al.
Publicado: (2020)

AaPDR3, a PDR Transporter 3, Is Involved in Sesquiterpene β-Caryophyllene Transport in Artemisia annua
por: Fu, Xueqing, et al.
Publicado: (2017)

Prevalence and risk factors of needle stick and sharp injury among tertiary hospital workers, Vientiane, Lao PDR
por: Matsubara, Chieko, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1dbctao160shuc2iovasgcb9hk